Clinical trial · Interventional
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma
Phase I/II Study of EBV-LMP1 Targeted DNAzyme in Nasopharyngeal Carcinoma
NCT01449942CI-TRIAL-00005606NPC-DZcompletedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether an EBV-LMP1 targeted DNAzyme is effective in radiosensitization of nasopharyngeal carcinoma in combination with standard radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNAzyme targeting EBV-LMP1 (DZ1) | Biological | — | UNRESOLVED |
| Saline | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- DZ1
- description
- DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
- interventionNames
- Biological: DNAzyme targeting EBV-LMP1 (DZ1)
- Other: Saline
- type
- PLACEBO_COMPARATOR
- label
- Saline
- description
- Placebo group receives saline injection in combination with radiation therapy.
- interventionNames
- Biological: DNAzyme targeting EBV-LMP1 (DZ1)
- Other: Saline
Primary outcomes (1)
- measure
- Tumor regression rate measured by MRI
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of nasopharyngeal squamous carcinoma * EBV-LMP1 positive * Signed Informed Consent Form Exclusion Criteria: * Abnormal laboratory results within 45 days prior to study entry * Participation in any study involving an experimental drug or an experimental medical device in 30 days prior to study entry * Current pregnancy * Inability to provide informed consent
References
Publications (9)
- BACKGROUNDYang L, Lu Z, Ma X, Cao Y, Sun LQ. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules. 2010 Sep 1;15(9):6127-39. doi: 10.3390/molecules15096127. PMID 20877211
- BACKGROUNDLu ZX, Ma XQ, Yang LF, Wang ZL, Zeng L, Li ZJ, Li XN, Tang M, Yi W, Gong JP, Sun LQ, Cao Y. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett. 2008 Jul 8;265(2):226-38. doi: 10.1016/j.canlet.2008.02.019. Epub 2008 Mar 18. PMID 18353539
- BACKGROUNDLu ZX, Ye M, Yan GR, Li Q, Tang M, Lee LM, Sun LQ, Cao Y. Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther. 2005 Jul;12(7):647-54. doi: 10.1038/sj.cgt.7700833. PMID 15803142
- BACKGROUNDDass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 2002 Oct;12(5):289-99. doi: 10.1089/108729002761381276. PMID 12477279
- BACKGROUNDSun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharmacol Rev. 2000 Sep;52(3):325-47. PMID 10977866
- BACKGROUNDCairns MJ, Hopkins TM, Witherington C, Wang L, Sun LQ. Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol. 1999 May;17(5):480-6. doi: 10.1038/8658. PMID 10331809
- BACKGROUNDCao Y, DePinho RA, Ernst M, Vousden K. Cancer research: past, present and future. Nat Rev Cancer. 2011 Sep 15;11(10):749-54. doi: 10.1038/nrc3138. PMID 21918542
- BACKGROUNDZheng H, Li LL, Hu DS, Deng XY, Cao Y. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol. 2007 Jun;4(3):185-96.